1. An aqueous pharmaceutical composition comprising insulin, an insulin analogue or an insulin derivative, or a pharmacologically compatible salt thereof, and methionine. The pharmaceutical composition according to claim 1, wherein the insulin is selected from the group consisting of human insulin, pig insulin and cattle insulin. The pharmaceutical composition according to claim 1, wherein the insulin analogue is selected from the group consisting of Gly (A21), Arg (B31), Arg (B32) human insulin, Lys (B3), Glu (B29) human insulin, Asp (B28) human insulin, Lys (B28), Pro (B29) human insulin, Des (B30) human insulin and an insulin analogue of the formula I, for example, A0 Lys or Arg； A5 Asp, Gln or Glu； A15 Asp, Glu or Gln； A18 Asp, Glu or Asn； B-1 Asp, Glu or amino； B0 Asp, Glu or chemical； B1 Asp, Glu or Phe； B2 Asp, Glu or Val； B3 Asp, Glu or Asn； B4 Asp, Glu or Gln； B29 Lys or chemical compound； B30 Thr or chemical compound； B31 Arg, Lys or chemical compound； B32 Arg amide, Lys amide or amino group respectively, the two amino acid residues in the group containing A5, A15, A18, B-1, B0, B1, B2, B3 and B4, simultaneously and independently from each other, correspond to Asp or Glu. 4. The pharmaceutical composition according to claim 3, wherein the insulin analogue selects a group containing Arg (A0), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Arg (B32) -NH human insulin , Arg (A0), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Lys (B32) -NHinsulin, Arg (A0), His (A8), Glu (A15), Asp (A18), Gly (A21), Arg (B31), Arg (B32) -NHinsulin, Arg (A0), His (A8), Glu (A15), Asp (A18), Gly (A21 ), Arg (B31), Lys (B32) -NH human insulin, Arg (A0), His (A8), Glu (A5), Glu (A15), Gly (A21), Arg (B31), Arg (B32) - Human NHinsulin, Arg (A0), His (A8), Glu (A5), Glu (A15), Gly (A21), Arg (B31), Lys (B32) -NH Human insulin, Arg (A0), His (A8) , Glu (A5), Gly (A21), Asp (B3), Arg (B31), Arg (B32) -NHinsulin, Arg (A0), His (A8), Glu (A5), Gly (A21), Asp (B3), Arg (B31)
